BRAF and MEK inhibitors (BRAF/MEKi) favor melanoma-infiltrating lymphocytes, providing the rationale for current combinatorial trials with anti-PD1 antibody. A portion of melanoma cells may express PD1, and anti-PD1 antibody could have a direct anti-tumor effect. Here, we explore if BRAF/MEKi modulate rates of PD1+ melanoma cells, supporting an additional - lymphocyte-independent - basis for their therapeutic combination with anti-PD1 antibody.

BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody

Sanlorenzo, Martina;Novelli, Mauro;Leuci, Valeria;Rotolo, Ramona;Donini, Chiara;Quaglino, Pietro;Fierro, Maria Teresa;Giordano, Silvia;Aglietta, Massimo;Sangiolo, Dario
2018

Abstract

BRAF and MEK inhibitors (BRAF/MEKi) favor melanoma-infiltrating lymphocytes, providing the rationale for current combinatorial trials with anti-PD1 antibody. A portion of melanoma cells may express PD1, and anti-PD1 antibody could have a direct anti-tumor effect. Here, we explore if BRAF/MEKi modulate rates of PD1+ melanoma cells, supporting an additional - lymphocyte-independent - basis for their therapeutic combination with anti-PD1 antibody.
24
14
3377
3385
BRAF, MEK inhibitors, PD1-positive, melanoma,lymphocyte-independent, synergism,anti-PD1, antibody
Sanlorenzo, Martina; Vujic, Igor; Floris, Arianna; Novelli, Mauro; Gammaitoni, Loretta; Giraudo, Lidia; Macagno, Marco; Leuci, Valeria; Rotolo, Ramona; Donini, Chiara; Basiricò, Marco; Quaglino, Pietro; Fierro, Maria Teresa; Giordano, Silvia; Sibilia, Maria; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario
File in questo prodotto:
File Dimensione Formato  
1078-0432.CCR-17-1914.full.pdf

embargo fino al 12/04/2019

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.89 MB
Formato Adobe PDF
1.89 MB Adobe PDF Visualizza/Apri
3377.full.pdf

non disponibili

Tipo di file: PDF EDITORIALE
Dimensione 1.17 MB
Formato Adobe PDF
1.17 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1666635
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact